FIGURE 1.

Biologics in severe asthma. Biologics (reported in bold) currently approved and used in the management of asthma have indications limited to patients with either eosinophilic or allergic phenotypes. Tezepelumab, an anti-TSLP monoclonal antibody that reduced exacerbations and improved lung function in a broad patients’ population with both type 2 and nontype 2 asthma, is a promising therapeutic approach in uncontrolled moderate-to-severe asthma irrespective of type 2 inflammatory biomarkers. TSLP, thymic stromal lymphopoietin.